X-Linked Retinoschisis

X-Linked Retinoschisis (XLRS) is a rare genetic eye condition that primarily affects boys and men. It causes the layers of the retina—the light-sensitive tissue at the back of the eye—to split or separate. This splitting, known as schisis, usually happens in the macula, which is the central part of the retina responsible for sharp, detailed vision. As a result, boys with XLRS often have blurry central vision and may have trouble reading or seeing fine details. The condition is usually noticed in childhood when a boy starts school, though it can sometimes be detected in infancy. The vision loss in XLRS is usually mild to moderate at first. While vision may worsen slightly during childhood and teenage years, it often stays relatively stable through early and middle adulthood. However, later in life, usually around the 50s or 60s, vision can decline further as the center of the retina begins to thin out. Some patients also develop splitting in the outer edges of the retina, which can increase the risk of more serious eye problems like bleeding inside the eye or a detached retina. These complications can cause sudden vision loss and require prompt medical attention. Because XLRS is a genetic condition linked to the X chromosome, it is passed down from mothers (who are usually carriers with normal vision) to their sons. Currently, there is no cure for XLRS, but regular eye exams are crucial to monitor the condition and catch any complications early. Glasses or low-vision aids can help maximize the vision a patient has, and researchers are actively studying new treatments, including gene therapy, which may offer hope for the future.

Condition category: Macular Dystrophy

Prevalence: 1 in 5,000-20,000

Inheritance patterns: X-Linked

Age of onset: Birth to first decade of life

Clinical overview: X-Linked Retinoschisis (XLRS) is a rare, inherited retinal dystrophy characterized by the splitting (schisis) of the neural retina, leading to progressive visual impairment. It is one of the most common causes of juvenile macular degeneration in males. The condition is caused by mutations in the RS1 gene, which encodes retinoschisin, a protein essential for intercellular adhesion and the structural integrity of the retina. The hallmark clinical feature is foveal schisis, which presents as a spoke-wheel pattern on the macula, often accompanied by peripheral retinoschisis in about half of the cases. The clinical significance of XLRS lies in its early onset, typically in the first decade of life, and its potential to cause significant visual morbidity. While the central vision loss is usually moderate and relatively stable during early adulthood, patients are at risk for severe complications such as vitreous hemorrhage and retinal detachment, particularly those with peripheral involvement. In later life, progressive macular atrophy can lead to legal blindness. XLRS is classified under OMIM #312700 (RETINOSCHISIS 1, X-LINKED, JUVENILE; RS1) and the causative gene RS1 is under OMIM *300839. The Orphanet classification number for the disease is ORPHA:792. Diagnosis relies on clinical examination, characteristic optical coherence tomography (OCT) findings, an electronegative electroretinogram (ERG), and genetic testing. Management is currently supportive, focusing on treating complications and optimizing remaining vision, though gene therapy trials are ongoing.

Patient and family guide: X-Linked Retinoschisis (XLRS) is a rare genetic eye condition that primarily affects boys and men. It causes the layers of the retina—the light-sensitive tissue at the back of the eye—to split or separate. This splitting, known as schisis, usually happens in the macula, which is the central part of the retina responsible for sharp, detailed vision. As a result, boys with XLRS often have blurry central vision and may have trouble reading or seeing fine details. The condition is usually noticed in childhood when a boy starts school, though it can sometimes be detected in infancy. The vision loss in XLRS is usually mild to moderate at first. While vision may worsen slightly during childhood and teenage years, it often stays relatively stable through early and middle adulthood. However, later in life, usually around the 50s or 60s, vision can decline further as the center of the retina begins to thin out. Some patients also develop splitting in the outer edges of the retina, which can increase the risk of more serious eye problems like bleeding inside the eye or a detached retina. These complications can cause sudden vision loss and require prompt medical attention. Because XLRS is a genetic condition linked to the X chromosome, it is passed down from mothers (who are usually carriers with normal vision) to their sons. Currently, there is no cure for XLRS, but regular eye exams are crucial to monitor the condition and catch any complications early. Glasses or low-vision aids can help maximize the vision a patient has, and researchers are actively studying new treatments, including gene therapy, which may offer hope for the future.

Symptoms and clinical features: The clinical presentation of X-Linked Retinoschisis varies significantly among individuals, but it typically follows a progressive course. In the early stages (infancy to first decade), the most common initial symptom is a decline in central visual acuity, often noticed when a child begins school and has difficulty reading or fails a vision screening. In some severe cases, infants may present with nystagmus (involuntary eye movements) or strabismus (misalignment of the eyes). The hallmark early sign is foveal schisis, visible as a spoke-wheel pattern of cystic spaces in the macula. Hyperopia (farsightedness) is also a common early finding. During the intermediate stages (second to fourth decades), visual acuity may deteriorate slightly but often remains relatively stable. The characteristic spoke-wheel pattern in the macula may become less distinct as the schisis cavities flatten. Patients may develop peripheral retinoschisis, typically in the inferotemporal quadrant, which can cause absolute scotomas (blind spots) in the peripheral visual field. It is during this stage that patients are at the highest risk for complications such as vitreous hemorrhage (bleeding into the eye) or retinal detachment, which can cause sudden, severe vision loss and require immediate surgical intervention. In the advanced stages (fifth decade and beyond), the disease is characterized by progressive outer retinal degeneration and macular atrophy. The cystic spaces in the macula often disappear completely, replaced by atrophic changes in the retinal pigment epithelium (RPE). This leads to a more significant and irreversible decline in central visual acuity, often resulting in legal blindness. The peripheral retina may also show signs of chronic changes, such as pigmentary disturbances, vascular attenuation, and white retinal flecks.

Molecular pathology: X-Linked Retinoschisis is caused by mutations in the RS1 gene, which encodes a 224-amino acid protein called retinoschisin. Retinoschisin is an adhesive protein secreted primarily by photoreceptors and bipolar cells in the retina. It contains a highly conserved discoidin domain, which is crucial for its function in cell-cell interactions and adhesion. In the normal retina, retinoschisin forms homo-oligomeric complexes (typically octamers) that are secreted into the extracellular matrix. These complexes bind tightly to the surface of photoreceptors and bipolar cells, interacting with other membrane proteins such as Na/K-ATPase, SARM1, and L-type voltage-gated calcium channels. Retinoschisin plays a critical role in maintaining the structural and functional integrity of the retina, particularly in the organization of the inner retinal layers and the formation and maintenance of the photoreceptor-bipolar cell synapse. Mutations in the RS1 gene disrupt the synthesis, folding, oligomerization, or secretion of retinoschisin. Many missense mutations within the discoidin domain prevent the proper folding and assembly of the retinoschisin octamers, leading to their retention and degradation within the endoplasmic reticulum of the photoreceptors. This lack of functional retinoschisin in the extracellular space compromises intercellular adhesion, leading to the characteristic splitting (schisis) of the neural retina, predominantly within the inner nuclear and outer plexiform layers. The disruption of the photoreceptor-bipolar synapse also accounts for the defective synaptic transmission observed as an electronegative ERG.

Genetics: X-Linked Retinoschisis is inherited in an X-linked recessive pattern. It is caused by mutations in the RS1 gene, located on chromosome Xp22.1-p22.3. Because males have only one X chromosome, a single mutated copy of the RS1 gene is sufficient to cause the disease. Females, who have two X chromosomes, are typically asymptomatic carriers if they inherit one mutated copy. A carrier female has a 50% chance of passing the mutation to her sons, who will be affected, and a 50% chance of passing it to her daughters, who will be carriers. The RS1 gene is the only gene known to be associated with XLRS. To date, over 190 different disease-causing mutations have been identified in the RS1 gene. These include missense, nonsense, frameshift, and splice-site mutations, as well as small deletions and insertions. The majority of these are missense mutations that affect the highly conserved discoidin domain of the retinoschisin protein. Despite the identification of numerous mutations, genotype-phenotype correlations in XLRS are generally weak. There is significant inter- and intrafamilial variability in disease severity, age of onset, and clinical presentation, even among individuals carrying the exact same RS1 mutation. Some studies have suggested that nonsense, splice-site, and frameshift mutations might be associated with a more severe phenotype or a higher frequency of electronegative ERG compared to missense mutations, but this is not consistently observed across all cohorts.

Diagnostic evaluation: The diagnosis of X-Linked Retinoschisis (XLRS) is primarily clinical, based on characteristic fundus findings and supported by imaging and electrophysiology. Fundoscopy typically reveals a spoke-wheel pattern of foveal schisis (splitting of the inner retinal layers) in almost all patients, best appreciated with red-free illumination. Peripheral retinoschisis, often in the inferotemporal quadrant, is present in approximately 50% of cases. Other fundus findings may include vitreous veils, retinal pigment epithelium (RPE) mottling, and in advanced stages, macular atrophy. Optical coherence tomography (OCT) is a critical diagnostic tool, demonstrating schisis cavities predominantly in the inner nuclear and outer plexiform layers, though they can involve multiple retinal layers. These cystoid spaces are most prominent in the fovea and perifoveal regions. Fundus autofluorescence (FAF) often shows a characteristic spoke-wheel pattern of hyper- and hypo-autofluorescence corresponding to the foveal schisis. Full-field electroretinogram (ffERG) typically shows an electronegative waveform in the dark-adapted state, characterized by a reduced b-wave amplitude with a relatively preserved a-wave, indicating inner retinal dysfunction at the level of the bipolar cells. Light-adapted responses may also show delayed and reduced cone responses. Pattern ERG often reveals a reduced P50 amplitude, reflecting central macular dysfunction. Differential diagnosis includes other causes of macular cysts or schisis, such as cystoid macular edema (CME), Goldmann-Favre syndrome (enhanced S-cone syndrome), autosomal dominant retinoschisis, and congenital stationary night blindness (CSNB). Genetic testing for mutations in the RS1 gene confirms the diagnosis and is essential for genetic counseling.

Differential diagnosis: Differential diagnosis of X-linked retinoschisis includes: (1) Cystoid macular edema — acquired, associated with uveitis, diabetes, or post-surgical; responds to anti-inflammatory treatment. (2) Goldmann-Favre syndrome — enhanced S-cone syndrome with retinoschisis, NR2E3 mutations. (3) Retinal detachment — rhegmatogenous, no spoke-wheel macular pattern. (4) Epiretinal membrane — macular distortion without true schisis cavities. (5) Nicotinic acid maculopathy — medication history, reversible. (6) Juvenile open-angle glaucoma — optic nerve cupping without macular schisis. (7) Familial exudative vitreoretinopathy — peripheral avascular retina, exudation, no macular schisis pattern.

Natural history: The onset of X-Linked Retinoschisis typically occurs in the first decade of life, often presenting when a child begins school and experiences reading difficulties or fails a vision screening. In some severe cases, it can present in infancy with nystagmus or strabismus. Visual acuity at initial presentation is usually between 20/60 and 20/120. The disease progression is generally slow and follows a characteristic timeline. Visual acuity may deteriorate slightly during the first and second decades of life but then tends to remain relatively stable throughout young adulthood and middle age. The schisis cavities in the macula may flatten or resolve over time, but this is often accompanied by progressive outer retinal degeneration and macular atrophy. A significant decline in visual acuity typically occurs again in the fifth or sixth decade of life, primarily due to the development of macular atrophy. By the sixth or seventh decade, visual acuity may drop to legal blindness (20/200 or worse). The natural history can be complicated at any age by acute events such as vitreous hemorrhage or retinal detachment, which are more common in patients with peripheral retinoschisis and can cause sudden, severe vision loss.

Management and treatment research: ### Current management and standard of care There is currently no cure for X-linked retinoschisis (XLRS), and no treatment has been proven to reliably stop or reverse the underlying retinal changes. Care focuses on monitoring the retina, treating complications, and supporting vision and daily activities. - **Regular retinal examinations and imaging** help monitor the macula, the central part of the retina used for detailed vision. Monitoring can also identify complications such as vitreous hemorrhage (bleeding into the gel-like material inside the eye) or retinal detachment. - **Glasses or contact lenses** may improve vision by correcting refractive errors, including farsightedness (hyperopia). - **Amblyopia treatment** may be important during childhood when vision differs between the eyes or when strabismus (eye misalignment) is present. - **Low-vision rehabilitation** can support school, work, and independence. Services may include magnifiers, electronic reading devices, large-print materials, accessibility technology, and orientation and mobility training. - **Carbonic anhydrase inhibitors (CAIs)**, such as dorzolamide eye drops or oral acetazolamide, may be considered for some people with fluid-filled schisis cavities in the macula. These medicines may reduce retinal fluid in some individuals, although improvement in vision is not guaranteed. - **Surgery** may be needed for complications such as retinal detachment or persistent vitreous hemorrhage. Preventive laser treatment for peripheral schisis is generally avoided because the retina can be fragile and laser may sometimes create retinal breaks. ### Approved therapies No therapies are currently approved specifically to treat the underlying genetic cause of XLRS. ### Investigational gene therapies Most XLRS is caused by disease-causing changes in the **RS1** gene. This gene provides instructions for retinoschisin, a protein that helps maintain retinal structure and communication between retinal cells. Gene augmentation therapy aims to provide retinal cells with a functional copy of **RS1**. - **ATSN-201** is an adeno-associated virus (AAV)-based gene augmentation therapy designed to deliver a functional **RS1** gene through an intravitreal injection, meaning an injection into the gel-like vitreous inside the eye. A Phase 3 study for people with RS1-associated XLRS is recruiting (**NCT05878860**). - **JWK002** is being studied in a recruiting early Phase 1 trial (**NCT06345898**). The study evaluates the safety and efficacy of a single subretinal injection, in which treatment is placed in the space beneath the retina during an eye procedure. - **IVB102** is being evaluated in an early Phase 1 study of safety and efficacy (**NCT06289452**). This study is active but not recruiting. Early-phase studies primarily assess safety, dose, and how a treatment behaves in the eye. They may not be designed to determine whether a treatment improves vision. ### Other investigational research - **LX103** is being evaluated in a recruiting study of people with XLRS (**NCT05814952**). Available study information describes an assessment of safety and efficacy; its mechanism and effectiveness have not been established. ### Considering clinical trial participation Clinical trials may provide access to investigational treatments and help advance XLRS research, but participation does not guarantee benefit. Studies may involve frequent visits, vision testing, retinal imaging, blood tests, eye injections, or surgical procedures. Recruiting registries and observational studies can also help researchers understand inherited retinal diseases and develop meaningful measures of vision and daily function. Current examples include the Inherited Retinal Degenerative Disease Registry (**NCT02435940**), DEFINE-IRD (**NCT07502664**), and an observational retinal-degeneration endpoint study (**NCT06375239**). A retinal specialist can help discuss whether a study may be appropriate.

Outlook: The visual prognosis for X-Linked Retinoschisis is variable but generally involves a slow, progressive decline in central vision. Most patients maintain reading vision (with or without low vision aids) and independence through their early adult years, as visual acuity tends to stabilize between the second and fifth decades of life. However, significant visual decline often occurs in the fifth or sixth decade due to progressive macular atrophy, frequently leading to legal blindness (visual acuity of 20/200 or worse). Quality of life can be significantly impacted by the visual impairment, affecting education, career choices, and daily activities such as driving. The prognosis is also heavily influenced by the occurrence of complications. Patients with peripheral retinoschisis are at a higher risk for vision-threatening events like vitreous hemorrhage and retinal detachment. Early detection and prompt surgical management of these complications are crucial to preserving vision. Regular monitoring and the use of low vision aids and educational support are essential for maximizing the patient's quality of life.

Epidemiology: X-Linked Retinoschisis is one of the most common inherited macular degenerations in males. The estimated prevalence ranges from 1 in 5,000 to 1 in 25,000 males worldwide. Because it is an X-linked recessive condition, it predominantly affects males. Female carriers are typically asymptomatic and rarely show any visual impairment or fundus abnormalities, although rare cases of affected females have been reported, usually in the context of consanguinity or homozygous mutations. There are no specific geographic or ethnic variations strongly associated with the condition, though founder effects may occur in isolated populations.

Selected references: 1. Sauer CG, Gehrig A, Warneke-Wittstock R, et al. Positional cloning of the gene associated with X-linked juvenile retinoschisis. Nat Genet. 1997;17(2):164-170. PMID: 9326935 2. George ND, Yates JR, Moore AT. X linked retinoschisis. Br J Ophthalmol. 1995;79(8):697-702. PMID: 7547781 3. Sikkink SK, Biswas S, Parry NR, Stanga PE, Trump D. X-linked retinoschisis: an update. J Med Genet. 2007;44(4):225-232. PMID: 17098887 4. Molday RS, Kellner U, Weber BH. X-linked juvenile retinoschisis: clinical diagnosis, genetic analysis, and molecular mechanisms. Prog Retin Eye Res. 2012;31(3):195-212. PMID: 22245536 5. Sieving PA, MacDonald IM, Hoang S. X-Linked Congenital Retinoschisis. 2003 Oct 24 [Updated 2020 Nov 5]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. PMID: 20301399 6. Wu WW, Wong JP, Kast J, Molday RS. RS1, a discoidin domain-containing retinal cell adhesion protein associated with X-linked retinoschisis, exists as a novel disulfide-linked octamer. J Biol Chem. 2005;280(11):10721-10730. PMID: 15632123 7. Renner AB, Kellner U, Cropp E, et al. Clinical and OCT features of X-linked retinoschisis. Graefes Arch Clin Exp Ophthalmol. 2008;246(12):1685-1694. PMID: 18688636